Compromised BRCA1-PALB2 interaction is associated with breast cancer risk

Oncogene

Volumn 36, Issue 29, 2017, Pages 4161-4170

  Foo, T K ^a   Tischkowitz, M ^b   Simhadri, S ^a   Boshari, T ^c   Zayed, N ^c   Burke, K A ^d   Berman, S H ^d   Blecua, P ^d   Riaz, N ^d   Huo, Y ^a   DIng, Y C ^e   Neuhausen, S L ^e   Weigelt, B ^d   Reis Filho, J S ^d   Foulkes, W D ^d   Xia, B ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c MCGILL UNIVERSITY   (Canada)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CHECKPOINT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LETROZOLE; MITOMYCIN; OLAPARIB; PALB2 PROTEIN; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; BRCA1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PALB2 PROTEIN, HUMAN; PROTEIN BINDING; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER RISK; CARCINOGENICITY; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GERMLINE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MALE BREAST CANCER; MEDICAL HISTORY; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INTERACTION; SANGER SEQUENCING; SIMPLE MASTECTOMY; VERY ELDERLY; WHOLE EXOME SEQUENCING; AMINO ACID SEQUENCE; BREAST TUMOR; GENETIC PREDISPOSITION; GENETIC TRANSFECTION; GENETICS; METABOLISM; MISSENSE MUTATION; PATHOLOGY; RISK; TUMOR CELL LINE;

AMINO ACID SEQUENCE; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION, MISSENSE; NUCLEAR PROTEINS; PROTEIN BINDING; RISK; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 85015676207     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2017.46     Document Type: Article

References (55)

1. Zhang F, Ma J, Wu J, Ye L, Cai H, Xia B et al. PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr Biol 2009; 19: 524-529.
2. Sy SM, Huen MS, Chen J. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci USA 2009; 106: 7155-7160.
3. Zhang F, Fan Q, Ren K, Andreassen PR. PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res 2009; 7: 1110-1118.
4. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 2006; 22: 719-729.
5. Tischkowitz M, Xia B. PALB2/FANCN: Recombining cancer and Fanconi anemia. Cancer Res 2010; 70: 7353-7359.
6. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 2011; 108: 18032-18037.
7. Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkas K, Roberts J et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med 2014; 371: 497-506.
8. Oliver AW, Swift S, Lord CJ, Ashworth A, Pearl LH. Structural basis for recruitment of BRCA2 by PALB2. EMBO Rep 2009; 10: 990-996.
9. Buisson R, Masson JY. PALB2 self-interaction controls homologous recombination. Nucleic Acids Res 2012; 40: 10312-10323.
10. Sy SM, Huen MS, Zhu Y, Chen J. PALB2 regulates recombinational repair through chromatin association and oligomerization. J Biol Chem 2009; 284: 18302-18310.
11. Casadei S, Norquist BM, Walsh T, Stray S, Mandell JB, Lee MK et al. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res 2011; 71: 2222-2229.
12. Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 2007; 39: 162-164.
13. Popova T, Manie E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 2012; 72: 5454-5462.
14. Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 2016; 534: 47-54.
15. Ding YC, Steele L, Kuan CJ, Greilac S, Neuhausen SL. Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat 2011; 126: 771-778.
16. Xia B, Dorsman JC, Ameziane N, de Vries Y, Rooimans MA, Sheng Q et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 2007; 39: 159-161.
17. Telli ML, Timms KM, Reid JE, Hennessy B, Mills GB, Jensen KC et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple negative breast cancer. Clin Cancer Res 2016; 22: 3764-3773.
18. Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014; 20: 764-775.
19. Huo Y, Cai H, Teplova I, Bowman-Colin C, Chen G, Price S et al. Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer. Cancer Discov 2013; 3: 894-907.
20. Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: Current data and future prospects. BMC Med 2015; 13: 188.
21. Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer 2016; 16: 110-120.
22. Hartford SA, Chittela R, Ding X, Vyas A, Martin B, Burkett S et al. Interaction with PALB2 is essential for maintenance of genomic integrity by BRCA2. PLoS Genet 2016; 12: E1006236.
23. Simhadri S, Peterson S, Patel DS, Huo Y, Cai H, Bowman-Colin C et al. Male fertility defect associated with disrupted BRCA1-PALB2 interaction in mice. The J Biol Chem 2014; 289: 24617-24629.
24. Wang L, Di LJ. BRCA1 and estrogen/estrogen receptor in breast cancer: Where they interact? Int J Biol Sci 2014; 10: 566-575.
25. Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G et al. Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci USA 2007; 104: 6788-6793.
26. Kohsaka S, Shukla N, Ameur N, Ito T, Ng CK, Wang L et al. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat Genet 2014; 46: 595-600.
27. Ho AS, Kannan K, Roy DM, Morris LG, Ganly I, Katabi N et al. The mutational landscape of adenoid cystic carcinoma. Nat Genet 2013; 45: 791-798.
28. Piscuoglio S, Burke KA, Ng CK, Papanastasiou AD, Geyer FC, Macedo GS et al. Uterine adenosarcomas are mesenchymal neoplasms. J Pathol 2016; 238: 381-388.
29. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
30. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A et al. The Genome analysis toolkit: A mapreduce framework for analyzing nextgeneration DNA sequencing data. Genome Res 2010; 20: 1297-1303.
31. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013; 31: 213-219.
32. Saunders CT, Wong WS, Swamy S, Becq J, Murray LJ, Cheetham RK. Strelka: Accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 2012; 28: 1811-1817.
33. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L et al. VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012; 22: 568-576.
34. Shen R, Seshan VE. FACETS: Allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res 2016; 44: E131.
35. Piscuoglio S, Ng CK, Murray MP, Guerini-Rocco E, Martelotto LG, Geyer FC et al. The genomic landscape of male breast cancers. Clin Cancer Res 2016; 22: 4045-4056.
36. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 2012; 30: 413-421.
37. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A et al. Mutational heterogeneity in cancer and the search for new cancerassociated genes. Nature 2013; 499: 214-218.
38. Schwarz JM, Rodelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 2010; 7: 575-576.
39. Carter H, Chen S, Isik L, Tyekucheva S, Velculescu VE, Kinzler KW et al. Cancer-specific high-throughput annotation of somatic mutations: Computational prediction of driver missense mutations. Cancer Res 2009; 69: 6660-6667.
40. Shihab HA, Gough J, Cooper DN, Stenson PD, Barker GL, Edwards KJ et al. Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. Hum Mutat 2013; 34: 57-65.
41. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C et al. Mutational landscape and significance across 12 major cancer types. Nature 2013; 502: 333-339.
42. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014; 505: 495-501.
43. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R et al. A census of human cancer genes. Nat Rev Cancer 2004; 4: 177-183.
44. Hu Y, Yan C, Hsu CH, Chen QR, Niu K, Komatsoulis GA et al. OmicCircos: A simpleto-use r package for the circular visualization of multidimensional omics data. Cancer Inform 2014; 13: 13-20.
45. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV et al. Signatures of mutational processes in human cancer. Nature 2013; 500: 415-421.
46. Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR. Deciphering signatures of mutational processes operative in human cancer. Cell Rep 2013; 3: 246-259.
47. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
48. Tischkowitz M, Sabbaghian N, Ray AM, Lange EM, Foulkes WD, Cooney KA. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer. Prostate 2008; 68: 675-678.
49. Bogdanova N, Sokolenko AP, Iyevleva AG, Abysheva SN, Blaut M, Bremer M et al. PALB2 mutations in German and Russian patients with bilateral breast cancer. Breast Cancer Res Treat 2011; 126: 545-550.
50. Nguyen-Dumont T, Hammet F, Mahmoodi M, Tsimiklis H, Teo ZL, Li R et al. Mutation screening of PALB2 in clinically ascertained families from the Breast Cancer Family Registry. Breast Cancer Res Treat 2015; 149: 547-554.
51. Zheng Y, Zhang J, Niu Q, Huo D, Olopade OI. Novel germline PALB2 truncating mutations in African American breast cancer patients. Cancer 2012; 118: 1362-1370.
52. Ding YC, Steele L, Chu LH, Kelley K, Davis H, John EM et al. Germline mutations in PALB2 in African-American breast cancer cases. Breast Cancer Res Treat 2011; 126: 227-230.
53. Teo Z, Park DJ, Provenzano E, Chatfield CA, Odefrey FA, Nguyen-Dumont T et al. Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families. Breast Cancer Res 2013; 15: R17.
54. Blanco A, de la Hoya M, Osorio A, Diez O, Miramar MD, Infante M et al. Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases. PLoS One 2013; 8: E67538.
55. Tischkowitz M, Capanu M, Sabbaghian N, Li L, Liang X, Valleé MP et al. Rare germline mutations in PALB2 and breast cancer risk: A population-based study. Hum Mutat 2012; 33: 674-680.